NEUROCRINE BIOSCIENCES INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, new issues for fiscal 2015 was $270.69M, a 103.26% increase from fiscal 2014.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, new issues for fiscal 2014 was $133.17M.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, new issues for fiscal 2012 was $82.97M.
- NEUROCRINE BIOSCIENCES INC stock issued during period, value, new issues for fiscal 2010 was $21.36M, a 115.74% increase from fiscal 2009.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2015-12-31 | $270.69M 10-K · filed 2018-02-13 | |
| 2014-12-31 | $133.17M 10-K · filed 2017-02-14 | |
| 2012-12-31 | $82.97M 10-K · filed 2015-02-09 | |
| 2010-12-31 | $21.36M 10-K · filed 2013-02-08 | |
| 2009-12-31 | $9.90M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |